The Europe late-stage chronic kidney disease drugs market is expected to reach US$ 2,919.58 million by 2027 from US$ 1,256.98 million in 2019; it is estimated to grow at a CAGR of 11.3% from 2020 to 2027.
The high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policies for the late-stage chronic kidney disease treatments are among the prime factors furling the market growth in this region. However, delay in the diagnosis of chronic kidney disease hampers the growth of the market.
In late-stage renal disease, kidneys lose their ability to filter waste and excess fluid from blood, which leads to waste accumulation in the body. Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. As per a research studypublished by the Public Library of Science (PLOS) in April 2020, CKD is estimated to have a prevalence of 2–7% in the adult German population, and the number of people opting for the targeted treatment is expected to increase with rising awareness about this condition. Moreover, the rising prevalence of hypertension and diabetes is a major cause of the progression of end-stage kidney disease (ESKD). These factors are expected to enhance market growth during the forecast period. Also, various strategies put forth by the World Health Organisation (WHO) to help policymakers in developing suitable policies, entailing the vital medicine list concept and the universal health coverage (UHC) approach, would boost the market growth in the coming years.
The COVID-19 pandemic has negatively impacted Europe late-stage chronic kidney disease drugs market. Elderly people and kidney disease patients seem to be at higher risk for more serious COVID-19 illness. However, Nephrology societies have made suggestions and provided guidelines to prevent COVID-19 transmission in dialysis facilities and to provide emergency services for patients. Therefore, the late-stage chronic kidney disease drugs market is expected to regain traction in the coming months.
Based on product type, Europelate-stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the largest share of the market in 2019, and it is expected to register the highest CAGR in the market during 2020–2027.
The Europe late-stage chronic kidney disease drugs market, by indication, is segmented into late-stage chronic kidney disease induced hyperparathyroidism, late-stage chronic kidney disease induced hyperphosphatemia, and late-stage chronic kidney disease induced hyperkalemia. The late-stage chronic kidney disease induced hyperparathyroidism segment held the largest share of the market in 2019, and it is estimated to register the highest CAGR in during the forecast period.
On the basis of distribution channel, the Europelate-stage chronic kidney disease drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest share of the market in 2019; however, the market for online pharmacies is expected to grow at the highest CAGR from 2020 to 2027.
A few of the primary and secondary sources associated with report on the Europelate-stage chronic kidney disease drugs market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH).